Inactive Instrument

Highlights Entasis Therapeutics Holdings Inc.

Equities

ETTX

US2936141033

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022	22-10-19	CI
Innoviva Acquires Remaining Stake in Entasis Therapeutics	22-07-11	MT
Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.	22-07-10	CI
Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell	22-05-23	MT
Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference	22-05-17	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference	22-04-26	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
Entasis Therapeutics Receives Cash Buyout Proposal From Innoviva at $1.80/Share; Shares Slide After-Hours	22-02-02	MT
Innoviva, Inc. entered into a definitive agreement to acquire to acquire remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders for $47.9 million.	22-02-01	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Zai Lab Limited and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (Sul-Dur) from Phase 3 Attack Trial	21-10-19	CI
Entasis Therapeutics Announces Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial	21-10-18	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
Entasis Therapeutics Holdings Inc. and Zai Lab Limited Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam	21-07-27	CI
Entasis Therapeutics Holdings Inc. Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens	21-07-01	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-05	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-23	CI
Entasis Therapeutics Holdings Inc. Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S	21-01-26	CI
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Entasis Therapeutics Holdings Inc.

Equities

ETTX

US2936141033

Highlights

Filters